>
Company >
History
-
2024
-
Prostate cancer treatment selected as Korea Drug Development Project
-
2023
-
‘AML treatment’, selected as 2023 Korea Drug Development Fund project
-
Relocation of research institute (JW Office)
-
2022
-
Selected as ‘The Excellent Company Research Institute
-
2021
-
‘Atopic treatment’, selected as 2021 Korea Drug Development Fund project
-
Completed phase 2b of gout treatment
-
2020
-
License out of the new drug candidates for the STAT3 next generation
targeted agents (ST-2286)
-
Completed phase 1 clinical trial for atopic treatment
-
Targeted anticancer drug Preclinical candidate material license out (JW Pharmaceutical)
-
2019
-
Gout treatment third party license out (Simcere)
-
2018
-
Third-party license out of atopy treatment (Leo Pharma.)
-
A*STAR (Agency of Science, Technology and Research)
affiliated research institutes (SRIS, SIgN, GIS, IMB) and
Singapore National Skin Center (NSC) joint research start
-
2017
-
Licensed out of preclinical candidates for atopy treatment (JW Pharmaceutical)
-
2016
-
Completed phase 2a of gout treatment
-
2014
-
Entry into phase II clinical study of anti-gout drug
-
2013
-
Completion of phase I clinical study of anti-gout drug
-
2012
-
International Symposium in commemoration of 20th
Anniversary
(“Challenge to Innovative Research & Development in
Cancer Therapy”)
-
Relocation of research institute (DRC, Natural science
campus in Sungkyunkwan University)
-
2010
-
Foundation of Clinical Research Center
-
License-out of drug candidates for anti-gout disease
-
2008
-
Publication of company history in commemoration of
15th Anniversary
-
2002
-
International Symposium in commemoration of 10th
Anniversary
-
2001
-
License-out of anti-breast Cancer and anti-IBS
(Irritable Bowel Syndrome) drug candidates
-
1992
-
Establishment of C&C Research Laboratories (1992. 01. 31)
